RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors
January 03, 2019 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Jan. 03, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of...
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
December 10, 2018 08:35 ET
|
RespireRX Pharmaceuticals Inc.
December 11 – 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston, MA SVP R&D leading workshop on Financial Planning and Commercial DevelopmentSVP R&D to present...
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
September 10, 2018 15:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...
RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data:
July 25, 2018 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain Glen Rock, N.J., July 25, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI)...
RespireRx Pharmaceuticals Inc. Announces Resignation of Dr. James S. Manuso
June 19, 2018 16:14 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. announces the decision of Dr. James S. Manuso to resign as president, CEO, Vice Chairman and member of the Board of...
Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.
June 19, 2018 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter...